Di Minno, GiovanniNavarro, DavidPerno, Carlo FedericoCanaro Hirnyk, MarianaGuertler, LutzIronside, James WEichler, HermannTiede, Andreas2024-07-112024-07-112017-08Di Minno Giovanni, Navarro David, Perno Carlo Federico, Canaro Hirnyk Mariana, Guertler Lutz, Ironside James W., et al. Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?. Ann Hematol. 2017 Aug;96(8):1253-1270. Epub 2017 Jun 18.0939-5555http://hdl.handle.net/20.500.13003/9729http://hdl.handle.net/20.500.12105/20491Patients with blood disorders (including leukaemia, platelet function disorders and coagulation factor deficiencies) or acute bleeding receive blood-derived products, such as red blood cells, platelet concentrates and plasma-derived products. Although the risk of pathogen contamination of blood products has fallen considerably over the past three decades, contamination is still a topic of concern. In order to counsel patients and obtain informed consent before transfusion, physicians are required to keep up to date with current knowledge on residual risk of pathogen transmission and methods of pathogen removal/inactivation. Here, we describe pathogens relevant to transfusion of blood products and discuss contemporary pathogen removal/inactivation procedures, as well as the potential risks associated with these products: the risk of contamination by infectious agents varies according to blood product/region, and there is a fine line between adequate inactivation and functional impairment of the product. The cost implications of implementing pathogen inactivation technology are also considered.enghttp://creativecommons.org/licenses/by/4.0/PathogenInactivationVirusRemovalBloodClottingBleeding disorderInfection riskPatient informationBlood Coagulation DisordersHemorrhagic DisordersBlood SafetyBlood TransfusionBlood-Borne PathogensRisk AssessmentRisk FactorsSepsisDisinfectionHumansPathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?review articleAttribution 4.0 International286249069681253-127010.1007/s00277-017-3028-41432-0584Annals of Hematologyopen accessFactores de RiesgoHumanosDesinfecciónMedición de RiesgoPatógenos Transmitidos por la SangreTrastornos de la Coagulación SanguíneaSepsisTransfusión SanguíneaTrastornos HemorrágicosSeguridad de la Sangre2-s2.0-85020513631404207100002L616848849